Sadeh M

Wolfson Medical Center

2
EM Publications
40
h-index
(6,182 citations, 156 total works)

Research Topics

Muscle Physiology and Disorders (21) Genetic Neurodegenerative Diseases (18) Cardiomyopathy and Myosin Studies (17) Inflammatory Myopathies and Dermatomyositis (16) Botulinum Toxin and Related Neurological Disorders (10)

Erythromelalgia Publications

Chronic non-paroxysmal neuropathic pain - Novel phenotype of mutation in the sodium channel SCN9A gene.

Dabby R, Sadeh M, Gilad R, Lampl Y, Cohen S , et al.
Journal of the neurological sciences

Gain-of-function mutations in the SCN9A gene (encoding to NaV1.7 voltage-gated sodium channel) cause two rare paroxysmal pain disorders: inherited erythromelalgia (IEM) and paroxysmal extreme pain disorder (PEDP). These phenotypes are characterized by episodic extreme localized pain with cutaneous autonomic signs. So far, no other phenotypes have been associated with mutation in the SCN9A gene. To investigate mutations in the SCN9A gene in patients with chronic non-paroxysmal neuropathic pain. 9 patients with chronic severe unexplained neuropathic pain. Of the nine patients one had predicted pathologic mutations in the SCN9A gene. This patient had a heterozygous change of n.4648 T-C in exon 27 resulting in a substitution of W1550R, a highly conserved amino acid, predicting damage in the transmembrane S2 region, repeat IV. This mutation was not found in 50 controls. SCN9A mutations cause pain syndromes other than IEM and PEPD. These mutations should be considered in patients with resistant unexplained chronic neuropathic pain.

Acute steroid responsive small-fiber sensory neuropathy: a new entity?

Dabby R, Gilad R, Sadeh M, Lampl Y, Watemberg N
Journal of the peripheral nervous system : JPNS

Small-fiber neuropathy is often idiopathic and commonly follows a chronic course. Treatment is often effective in treating the core symptom of pain, but it has no effect on the pathologic process. We describe four patients with acute small-fiber neuropathy who responded dramatically to steroid therapy. All patients had acute onset neuropathic pain, normal nerve conduction studies, and evidence of small-fiber dysfunction in quantitative sensory testing and skin biopsy. Symptoms were distal and symmetrical in three patients and generalized in one patient. In two cases, the neuropathy presented as an erythromelalgia-like syndrome. Marked clinical improvement occurred 1-2 weeks after oral prednisone therapy was initiated. Three patients remained symptom free, and one patient experienced recurrence of neuropathy after prednisone was tapered.